Trinity Biotech (TRIB) has released an update.
Trinity Biotech plc has announced a significant increase in orders for its TrinScreen HIV test, leading to an upward revision of its 2024 sales forecast to $10 million, a substantial increase from the previously projected $8 million. This uptick in demand has been met with an expansion in production capacity by the company. Additionally, in response to a recent WHO Public Health Emergency, Trinity Biotech has boosted manufacturing for its FDA-cleared viral transport medium, FlexTrans™, to support global health diagnostic testing.
For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.
